Register Login

LIGAND PHARMACEUTICALS INC (LGND)

Reardon Andrew 🟡 adjusted position in 5.0K shares (1 derivative) of LIGAND PHARMACEUTICALS INC (LGND) at $230.41 ($1.7M) Transaction Date: Jun 01, 2026 | Filing ID: 000083

Full text
Register to leave comments
  • News bot June 2, 2026, 10:22 p.m.

    🔍 Reardon Andrew (Executive)

    Company: LIGAND PHARMACEUTICALS INC (LGND)

    Report Date: 2026-06-01

    Transaction Summary:

    • Total transactions: 9
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 5,000
    • Total shares sold: 10,000

    Detailed Transactions and Holdings:

    • Acquired 5,000 shares of Common Stock at $52.27 per share (Direct)
      Date: 2026-06-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 46,382.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 491 shares of Common Stock at $223.9467 per share (Direct)
      Date: 2026-06-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 45,891.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Sold 677 shares of Common Stock at $225.1983 per share (Direct)
      Date: 2026-06-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 45,214.00 | transaction_form_type: 4 | Footnotes: F1, F3
    • Sold 1,432 shares of Common Stock at $225.9672 per share (Direct)
      Date: 2026-06-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 43,782.00 | transaction_form_type: 4 | Footnotes: F1, F4
    • Sold 400 shares of Common Stock at $226.7794 per share (Direct)
      Date: 2026-06-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 43,382.00 | transaction_form_type: 4 | Footnotes: F1, F5
    • Sold 584 shares of Common Stock at $228.5738 per share (Direct)
      Date: 2026-06-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 42,798.00 | transaction_form_type: 4 | Footnotes: F1, F6
    • Sold 1,216 shares of Common Stock at $229.4676 per share (Direct)
      Date: 2026-06-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 41,582.00 | transaction_form_type: 4 | Footnotes: F1, F7
    • Sold 200 shares of Common Stock at $230.41 per share (Direct)
      Date: 2026-06-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 41,382.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 5,000 shares of Employee Stock Option (right to buy) at $52.27 per share (Derivative)
      Date: 2026-06-01 | Code: M | Expires: 2032-08-01 | equity_swap_involved: 0 | shares_owned_after: 39,444.00 | transaction_form_type: 4 | Footnotes: F1, F8

    Footnotes:

    • F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1.
    • F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $223.4250 to $224.3800. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $224.5100 to $225.4600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $225.5200 to $226.3700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F5: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $226.5250 to $227.0100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F6: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $228.0500 to $228.9650. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F7: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $229.0900 to $230.0000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F8: The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter.

Search

News categories